#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Atypical haemolytic uraemic syndrome Epstein-Barr virus associated lymphoproliferative disorder Breast cancer metastatic Brain injury Craniopharyngioma Cardiac failure acute Urea cycle disorder Encephalopathy neonatal Selective polysaccharide antibody deficiency Penile cancer Malignant central nervous system neoplasm Pituitary-dependent Cushing's syndrome Nephrotic syndrome Glomerulonephritis membranous Subdural haematoma More trials…

    Learn about Rare Diseases

    Alport’s syndrome – Treatment Nodal marginal zone B-cell lymphoma – Life with Disease Angiosarcoma non-metastatic – Diagnostics Haemophagocytic lymphohistiocytosis – Trials in Disease Alternating hemiplegia of childhood – Diagnostics Ewing’s sarcoma – Trials in Disease Adrenogenital syndrome – Basic Information Leukoencephalopathy – Trials in Disease Undifferentiated sarcoma – Treatment Progressive supranuclear palsy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dextrose Bp Vemurafenib ZOLPIDEM TARTRATE Img-007 Relatlimab Foscarnet Sodium Hexahydrate Litifilimab Ly3871801 L-PROLINE Pemafibrate Clindamycin Psma-11 Doxecitine Tamibarotene Duloxetine Specific Nucleic Acid Sna-Xfsc SUMATRIPTAN Danazol Rezafungin Acetate Allo-501A More therapies…

    Learn about Your Condition

    Encephalitis Japanese B Neurodevelopmental disorder Anxiety Acute respiratory failure Developmental hip dysplasia Liver transplant Hypersomnia Rectal cancer stage II Astrocytoma malignant Asthmatic crisis Neutropenia Mixed dementia Chordoma Pruritus Neonatal respiratory failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Casa Di Cura Accreditata Istituto Chirurgico Ortopedico…

Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali

Via Franco Faggiana 1668, Latina, 04100, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

    Recruiting

    3 1 1
    Investigated Drugs:
    • ICEF15
    • Placebo
    Austria Bulgaria Czechia France Germany Italy +4

  • Study on Surgical Treatment with or without Apalutamide for Patients with High-Risk Prostate Cancer Eligible for Radical Prostatectomy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Apalutamide
    Italy

  • Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    • Obesity
    Bulgaria Czechia Denmark France Germany Greece +4

  • Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    • Obesity
    • Overweight
    Bulgaria Czechia Denmark France Germany Greece +4

  • Effect of semaglutide, acetylsalicylic acid, and clopidogrel on blood clotting in patients with diabetes or overweight with cardiovascular disease

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    • Semaglutide
    Italy

  • A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

    Not recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Ziltivekimab
    Bulgaria Czechia Denmark France Germany Greece +4

  • Study of rimegepant for preventing chronic migraine in adolescents aged 12 to 17 years

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Czechia Finland Hungary Italy Poland Slovakia +1

  • Study on Atogepant for Preventing Menstrual Migraine in Women

    Not recruiting

    3 1
    Investigated Drugs:
    • Atogepant
    Czechia Germany Hungary Italy Poland Portugal +1

  • Study on Atogepant for Treating Migraine in Patients: Evaluating Effectiveness and Safety

    Not recruiting

    3 1
    Investigated Diseases:
    • Migraine with aura
    • Migraine without aura
    • Migraine
    Investigated Drugs:
    • Atogepant
    Belgium Czechia Germany Hungary Italy Poland +4

  • Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!